Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jun 11;12(6):e008475.
doi: 10.1136/jitc-2023-008475.

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

Jiwei Huang #  1 , Yueming Wang #  2 , Fan Xu #  2 , Zaoyu Wang #  3 , Guangyu Wu #  4 , Wen Kong #  2 , N G Cheoklong #  2 , Thibault Tricard  5 , Xiaorong Wu  2 , Wei Zhai  2 , Wei Zhang  6 , Jiyang Zhang  6 , Ding Zhang  7 , Shuyin Chen  8 , Yuqing Lian  8 , Yonghui Chen  1 , Jin Zhang  1 , Yiran Huang  1 , Wei Xue  1
Affiliations
Clinical Trial

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

Jiwei Huang et al. J Immunother Cancer. .

Abstract

Background: A combination of axitinib and immune checkpoint inhibitors (ICIs) demonstrated promising efficacy in the treatment of advanced renal cell carcinoma (RCC). This study aims to prospectively evaluate the safety, efficacy, and biomarkers of neoadjuvant toripalimab plus axitinib in non-metastatic clear cell RCC.

Methods: This is a single-institution, single-arm phase II clinical trial. Patients with non-metastatic biopsy-proven clear cell RCC (T2-T3N0-1M0) are enrolled. Patients will receive axitinib 5 mg twice daily combined with toripalimab 240 mg every 3 weeks (three cycles) for up to 12 weeks. Patients then will receive partial (PN) or radical nephrectomy (RN) after neoadjuvant therapy. The primary endpoint is objective response rate (ORR). Secondary endpoints include disease-free survival, safety, and perioperative complication rate. Predictive biomarkers are involved in exploratory analysis.

Results: A total of 20 patients were enrolled in the study, with 19 of them undergoing surgery. One patient declined surgery. The primary endpoint ORR was 45%. The posterior distribution of πORR had a mean of 0.44 (95% credible intervals: 0.24-0.64), meeting the predefined primary endpoint with an ORR of 32%. Tumor shrinkage was observed in 95% of patients prior to nephrectomy. Furthermore, four patients achieved a pathological complete response. Grade ≥3 adverse events occurred in 25% of patients, including hypertension, hyperglycemia, glutamic pyruvic transaminase/glutamic oxaloacetic transaminase (ALT/AST) increase, and proteinuria. Postoperatively, one grade 4a and eight grade 1-2 complications were noted. In comparison to patients with stable disease, responders exhibited significant differences in immune factors such as Arginase 1(ARG1), Melanoma antigen (MAGEs), Dendritic Cell (DC), TNF Superfamily Member 13 (TNFSF13), Apelin Receptor (APLNR), and C-C Motif Chemokine Ligand 3 Like 1 (CCL3-L1). The limitation of this trial was the small sample size.

Conclusion: Neoadjuvant toripalimab combined with axitinib shows encouraging activity and acceptable toxicity in locally advanced clear cell RCC and warrants further study.

Trial registration number: clinicaltrials.gov, NCT04118855.

Keywords: Immune Checkpoint Inhibitors; Renal Cell Carcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SC and YL, employees of Shanghai Junshi Biosciences Inc. WZ, JZ, and DZ, employees of 3D Medicines Inc. Other authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
Trial design and profile. (A) Study schema. (B) Trial profile. Twice a day.
Figure 2
Figure 2
Treatment response. (A) Spider plot of tumor response evaluated by radiological imaging. (B) Waterfall plot of tumor response. (C) The change between clinical T stage and pathological T stage.
Figure 3
Figure 3
Treatment follow-up. (A) Swimmer plot. (B) Disease-free survival.
Figure 4
Figure 4
(A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD-L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Babaian KN, Kim DY, Kenney PA, et al. . Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol 2015;193:1101–7. 10.1016/j.juro.2014.10.096 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Choueiri TK, Tomczak P, Park SH, et al. . Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:683–94. 10.1056/NEJMoa2106391 - DOI - PubMed
    1. Ravaud A, Motzer RJ, Pandha HS, et al. . Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246–54. 10.1056/NEJMoa1611406 - DOI - PubMed
    1. Ingels A, Campi R, Capitanio U, et al. . Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022;19:391–418. 10.1038/s41585-022-00592-3 - DOI - PubMed

Publication types

MeSH terms

Associated data